262 related articles for article (PubMed ID: 34247299)
1. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
4. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
5. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
8. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
11. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
15. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lyu M; Jiang E; He Y; Yang D; Ma Q; Pang A; Zhai W; Wei J; Huang Y; Zhang G; Zhang R; Feng S; Han M
Hematology; 2021 Dec; 26(1):65-74. PubMed ID: 33402056
[No Abstract] [Full Text] [Related]
16. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
[TBL] [Abstract][Full Text] [Related]
18. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
[TBL] [Abstract][Full Text] [Related]
20. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
